Imatinib therapy for chronic myeloid leukemia: Where do we go now?

被引：5

作者：

Cortes, Jorge E. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 20期

关键词：

D O I：

10.1200/JCO.2008.16.9870

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3308 / 3309

页数：2

共 14 条

[1]

Aoki E, 2006, J CLIN ONCOL, V24, p345S

[2] Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia [J].

Baccarani, M ;

Martinelli, G ;

Rosti, G ;

Trabacchi, E ;

Testoni, N ;

Bassi, S ;

Amabile, M ;

Soverini, S ;

Castagnetti, F ;

Cilloni, D ;

Izzo, B ;

de Vivo, A ;

Messa, E ;

Bonifazi, F ;

Poerio, A ;

Luatti, S ;

Giugliano, E ;

Alberti, D ;

Fincato, G ;

Russo, D ;

Pane, F ;

Saglio, G .

BLOOD, 2004, 104 (13) :4245-4251

[3] BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria [J].

Branford, Susan ;

Seymour, John F. ;

Grigg, Andrew ;

Arthur, Chris ;

Rudzki, Zbigniew ;

Lynch, Kevin ;

Hughes, Timothy .

CLINICAL CANCER RESEARCH, 2007, 13 (23) :7080-7085

[4]

CORTES J, 2007, BLOOD, V110

[5] Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis [J].

de Lavallade, Hugues ;

Apperley, Jane F. ;

Khorashad, Jamshid S. ;

Milojkovic, Dragana ;

Reid, Alistair G. ;

Bua, Marco ;

Szydlo, Richard ;

Olavarria, Eduardo ;

Kaeda, Jaspal ;

Goldman, John M. ;

Marin, David .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (20) :3358-3363

[6] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J].

Druker, Brian J. ;

Guilhot, Francois ;

O'Brien, Stephen G. ;

Gathmann, Insa ;

Kantarjian, Hagop ;

Gattermann, Norbert ;

Deininger, Michael W. N. ;

Silver, Richard T. ;

Goldman, John M. ;

Stone, Richard M. ;

Cervantes, Francisco ;

Hochhaus, Andreas ;

Powell, Bayard L. ;

Gabrilove, Janice L. ;

Rousselot, Philippe ;

Reiffers, Josy ;

Cornelissen, Jan J. ;

Hughes, Timothy ;

Agis, Hermine ;

Fischer, Thomas ;

Verhoef, Gregor ;

Shepherd, John ;

Saglio, Giuseppe ;

Gratwohl, Alois ;

Nielsen, Johan L. ;

Radich, Jerald P. ;

Simonsson, Bengt ;

Taylor, Kerry ;

Baccarani, Michele ;

So, Charlene ;

Letvak, Laurie ;

Larson, Richard A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2408-2417

[7] Results of a prospective phase 2 study combining imatinib, mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase [J].

Gardembas, M ;

Rousselot, P ;

Tulliez, M ;

Vigier, M ;

Buzyn, A ;

Rigal-Huguet, F ;

Legros, L ;

Michallet, M ;

Berthou, C ;

Cheron, N ;

Maloisel, F ;

Mahon, FX ;

Facon, T ;

Berthaud, P ;

Guilhot, J ;

Guilhot, F .

BLOOD, 2003, 102 (13) :4298-4305

[8] Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy [J].

Hochhaus, Andreas ;

Kantarjian, Hagop M. ;

Baccarani, Michele ;

Lipton, Jeffrey H. ;

Apperley, Jane F. ;

Druker, Brian J. ;

Facon, Thierry ;

Goldberg, Stuart L. ;

Cervantes, Francisco ;

Niederwieser, Dietger ;

Silver, Richard T. ;

Stone, Richard M. ;

Hughes, Timothy P. ;

Muller, Martin C. ;

Ezzeddine, Rana ;

Countouriotis, Athena M. ;

Shah, Neil P. .

BLOOD, 2007, 109 (06) :2303-2309

[9] Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia [J].

Hughes, TP ;

Kaeda, J ;

Branford, S ;

Rudzki, Z ;

Hochhaus, A ;

Hensley, ML ;

Gathmann, I ;

Bolton, AE ;

van Hoomissen, IC ;

Goldman, JM ;

Radich, JP ;

Taylor, K ;

Durrant, S ;

Schwarer, A ;

Joske, D ;

Seymour, J ;

Grigg, A ;

Ma, D ;

Arthur, C ;

Bradstock, K ;

Joshua, D ;

Lechner, K ;

Verhoef, G ;

Louwagie, A ;

Martiat, P ;

Straetmans, N ;

Bosly, A ;

Shepherd, J ;

Shustik, C ;

Lipton, J ;

Kovacs, DM ;

Turner, AR ;

Nielsen, JL ;

Birgens, H ;

Bjerrum, OW ;

Guilhot, F ;

Reiffers, J ;

Rousselot, P ;

Facon, T ;

Harousseau, JL ;

Tulliez, M ;

Guerci, A ;

Blaise, D ;

Maloisel, F ;

Michallet, M ;

Fischer, T ;

Hossfeld, D ;

Mertelsmann, R ;

Andreesen, R ;

Nerl, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (15) :1423-1432

[10] High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia [J].

Kantarjian, H ;

Talpaz, M ;

O'Brien, SS ;

Garcia-Manero, G ;

Verstovsek, S ;

Giles, F ;

Rios, MB ;

Shan, JQ ;

Letvak, L ;

Thomas, D ;

Faderl, S ;

Ferrajoli, A ;

Cortes, J .

BLOOD, 2004, 103 (08) :2873-2878

← 1 2 →